nodes	percent_of_prediction	percent_of_DWPC	metapath
Lenalidomide—PTGS2—lung cancer	0.182	0.54	CbGaD
Lenalidomide—ABCB1—lung cancer	0.155	0.459	CbGaD
Lenalidomide—PTGS2—Cisplatin—lung cancer	0.0346	0.124	CbGbCtD
Lenalidomide—PTGS2—Etoposide—lung cancer	0.034	0.122	CbGbCtD
Lenalidomide—ABCB1—Topotecan—lung cancer	0.0287	0.103	CbGbCtD
Lenalidomide—ABCB1—Gefitinib—lung cancer	0.0262	0.0938	CbGbCtD
Lenalidomide—ABCB1—Vinorelbine—lung cancer	0.0202	0.0723	CbGbCtD
Lenalidomide—ABCB1—Crizotinib—lung cancer	0.0161	0.0575	CbGbCtD
Lenalidomide—ABCB1—Gemcitabine—lung cancer	0.0157	0.0562	CbGbCtD
Lenalidomide—ABCB1—Erlotinib—lung cancer	0.0155	0.0555	CbGbCtD
Lenalidomide—ABCB1—Paclitaxel—lung cancer	0.0142	0.0508	CbGbCtD
Lenalidomide—ABCB1—Irinotecan—lung cancer	0.014	0.0501	CbGbCtD
Lenalidomide—ABCB1—Vinblastine—lung cancer	0.0124	0.0445	CbGbCtD
Lenalidomide—ABCB1—Cisplatin—lung cancer	0.0114	0.0408	CbGbCtD
Lenalidomide—ABCB1—Etoposide—lung cancer	0.0112	0.0401	CbGbCtD
Lenalidomide—ABCB1—Docetaxel—lung cancer	0.0103	0.0367	CbGbCtD
Lenalidomide—ABCB1—Doxorubicin—lung cancer	0.00765	0.0274	CbGbCtD
Lenalidomide—ABCB1—Methotrexate—lung cancer	0.00741	0.0265	CbGbCtD
Lenalidomide—CDH5—mammary gland—lung cancer	0.00614	0.102	CbGeAlD
Lenalidomide—TNFSF11—respiratory system—lung cancer	0.00544	0.0907	CbGeAlD
Lenalidomide—CDH5—respiratory system—lung cancer	0.00409	0.0682	CbGeAlD
Lenalidomide—CDH5—epithelium—lung cancer	0.00342	0.057	CbGeAlD
Lenalidomide—CDH5—bronchus—lung cancer	0.00337	0.0562	CbGeAlD
Lenalidomide—TNFSF11—bone marrow—lung cancer	0.00319	0.0532	CbGeAlD
Lenalidomide—CDH5—trachea—lung cancer	0.00302	0.0504	CbGeAlD
Lenalidomide—TNFSF11—lung—lung cancer	0.00289	0.0482	CbGeAlD
Lenalidomide—CDH5—cardiac atrium—lung cancer	0.00284	0.0474	CbGeAlD
Lenalidomide—CRBN—respiratory system—lung cancer	0.0026	0.0433	CbGeAlD
Lenalidomide—CDH5—bone marrow—lung cancer	0.0024	0.04	CbGeAlD
Lenalidomide—CDH5—lung—lung cancer	0.00217	0.0362	CbGeAlD
Lenalidomide—CRBN—bronchus—lung cancer	0.00214	0.0357	CbGeAlD
Lenalidomide—TNFSF11—lymph node—lung cancer	0.00198	0.0329	CbGeAlD
Lenalidomide—CRBN—trachea—lung cancer	0.00192	0.032	CbGeAlD
Lenalidomide—CRBN—cardiac atrium—lung cancer	0.0018	0.0301	CbGeAlD
Lenalidomide—CRBN—bone marrow—lung cancer	0.00152	0.0254	CbGeAlD
Lenalidomide—CDH5—lymph node—lung cancer	0.00149	0.0248	CbGeAlD
Lenalidomide—CRBN—lung—lung cancer	0.00138	0.023	CbGeAlD
Lenalidomide—CRBN—lymph node—lung cancer	0.000944	0.0157	CbGeAlD
Lenalidomide—Thalidomide—CYP2E1—lung cancer	0.000778	0.229	CrCbGaD
Lenalidomide—Thalidomide—CYP1A1—lung cancer	0.000768	0.226	CrCbGaD
Lenalidomide—Pomalidomide—PTGS2—lung cancer	0.000745	0.219	CrCbGaD
Lenalidomide—PTGS2—respiratory system—lung cancer	0.000708	0.0118	CbGeAlD
Lenalidomide—Pomalidomide—ABCB1—lung cancer	0.000633	0.186	CrCbGaD
Lenalidomide—PTGS2—epithelium—lung cancer	0.000592	0.00986	CbGeAlD
Lenalidomide—PTGS2—bronchus—lung cancer	0.000583	0.00971	CbGeAlD
Lenalidomide—PTGS2—trachea—lung cancer	0.000523	0.00872	CbGeAlD
Lenalidomide—Thalidomide—PTGS2—lung cancer	0.00048	0.141	CrCbGaD
Lenalidomide—ABCB1—respiratory system—lung cancer	0.000438	0.0073	CbGeAlD
Lenalidomide—PTGS2—bone marrow—lung cancer	0.000415	0.00692	CbGeAlD
Lenalidomide—PTGS2—lung—lung cancer	0.000376	0.00627	CbGeAlD
Lenalidomide—ABCB1—epithelium—lung cancer	0.000366	0.0061	CbGeAlD
Lenalidomide—ABCB1—trachea—lung cancer	0.000324	0.00539	CbGeAlD
Lenalidomide—PTGS2—lymph node—lung cancer	0.000257	0.00429	CbGeAlD
Lenalidomide—ABCB1—bone marrow—lung cancer	0.000257	0.00428	CbGeAlD
Lenalidomide—ABCB1—lung—lung cancer	0.000233	0.00388	CbGeAlD
Lenalidomide—ABCB1—lymph node—lung cancer	0.000159	0.00265	CbGeAlD
Lenalidomide—Pruritus—Gemcitabine—lung cancer	3.17e-05	0.000142	CcSEcCtD
Lenalidomide—Urethral disorder—Methotrexate—lung cancer	3.17e-05	0.000142	CcSEcCtD
Lenalidomide—Infection—Docetaxel—lung cancer	3.16e-05	0.000142	CcSEcCtD
Lenalidomide—Weight decreased—Doxorubicin—lung cancer	3.16e-05	0.000142	CcSEcCtD
Lenalidomide—Feeling abnormal—Etoposide—lung cancer	3.16e-05	0.000141	CcSEcCtD
Lenalidomide—Hyperglycaemia—Doxorubicin—lung cancer	3.15e-05	0.000141	CcSEcCtD
Lenalidomide—Diarrhoea—Irinotecan—lung cancer	3.15e-05	0.000141	CcSEcCtD
Lenalidomide—Pneumonia—Doxorubicin—lung cancer	3.13e-05	0.00014	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Etoposide—lung cancer	3.13e-05	0.00014	CcSEcCtD
Lenalidomide—Shock—Docetaxel—lung cancer	3.13e-05	0.00014	CcSEcCtD
Lenalidomide—Nervous system disorder—Docetaxel—lung cancer	3.12e-05	0.00014	CcSEcCtD
Lenalidomide—Thrombocytopenia—Docetaxel—lung cancer	3.12e-05	0.00014	CcSEcCtD
Lenalidomide—Infestation NOS—Doxorubicin—lung cancer	3.12e-05	0.000139	CcSEcCtD
Lenalidomide—Infestation—Doxorubicin—lung cancer	3.12e-05	0.000139	CcSEcCtD
Lenalidomide—Visual impairment—Methotrexate—lung cancer	3.11e-05	0.000139	CcSEcCtD
Lenalidomide—Tachycardia—Docetaxel—lung cancer	3.11e-05	0.000139	CcSEcCtD
Lenalidomide—Feeling abnormal—Paclitaxel—lung cancer	3.1e-05	0.000139	CcSEcCtD
Lenalidomide—Skin disorder—Docetaxel—lung cancer	3.09e-05	0.000138	CcSEcCtD
Lenalidomide—Stevens-Johnson syndrome—Doxorubicin—lung cancer	3.09e-05	0.000138	CcSEcCtD
Lenalidomide—Hypersensitivity—Cisplatin—lung cancer	3.08e-05	0.000138	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Paclitaxel—lung cancer	3.07e-05	0.000137	CcSEcCtD
Lenalidomide—Diarrhoea—Gemcitabine—lung cancer	3.07e-05	0.000137	CcSEcCtD
Lenalidomide—Renal failure—Doxorubicin—lung cancer	3.06e-05	0.000137	CcSEcCtD
Lenalidomide—Erythema multiforme—Methotrexate—lung cancer	3.05e-05	0.000137	CcSEcCtD
Lenalidomide—Neuropathy peripheral—Doxorubicin—lung cancer	3.05e-05	0.000137	CcSEcCtD
Lenalidomide—Dizziness—Irinotecan—lung cancer	3.05e-05	0.000136	CcSEcCtD
Lenalidomide—Urticaria—Etoposide—lung cancer	3.04e-05	0.000136	CcSEcCtD
Lenalidomide—Stomatitis—Doxorubicin—lung cancer	3.04e-05	0.000136	CcSEcCtD
Lenalidomide—Anorexia—Docetaxel—lung cancer	3.04e-05	0.000136	CcSEcCtD
Lenalidomide—Body temperature increased—Etoposide—lung cancer	3.03e-05	0.000136	CcSEcCtD
Lenalidomide—Abdominal pain—Etoposide—lung cancer	3.03e-05	0.000136	CcSEcCtD
Lenalidomide—Urinary tract infection—Doxorubicin—lung cancer	3.03e-05	0.000136	CcSEcCtD
Lenalidomide—Conjunctivitis—Doxorubicin—lung cancer	3.03e-05	0.000136	CcSEcCtD
Lenalidomide—Eye disorder—Methotrexate—lung cancer	3.02e-05	0.000135	CcSEcCtD
Lenalidomide—Tinnitus—Methotrexate—lung cancer	3.01e-05	0.000135	CcSEcCtD
Lenalidomide—Asthenia—Cisplatin—lung cancer	3e-05	0.000134	CcSEcCtD
Lenalidomide—Cardiac disorder—Methotrexate—lung cancer	3e-05	0.000134	CcSEcCtD
Lenalidomide—Sweating—Doxorubicin—lung cancer	2.99e-05	0.000134	CcSEcCtD
Lenalidomide—Urticaria—Paclitaxel—lung cancer	2.98e-05	0.000134	CcSEcCtD
Lenalidomide—Hypotension—Docetaxel—lung cancer	2.98e-05	0.000133	CcSEcCtD
Lenalidomide—Haematuria—Doxorubicin—lung cancer	2.97e-05	0.000133	CcSEcCtD
Lenalidomide—Body temperature increased—Paclitaxel—lung cancer	2.97e-05	0.000133	CcSEcCtD
Lenalidomide—Abdominal pain—Paclitaxel—lung cancer	2.97e-05	0.000133	CcSEcCtD
Lenalidomide—Hepatobiliary disease—Doxorubicin—lung cancer	2.95e-05	0.000132	CcSEcCtD
Lenalidomide—Epistaxis—Doxorubicin—lung cancer	2.94e-05	0.000132	CcSEcCtD
Lenalidomide—Angiopathy—Methotrexate—lung cancer	2.93e-05	0.000131	CcSEcCtD
Lenalidomide—Vomiting—Irinotecan—lung cancer	2.93e-05	0.000131	CcSEcCtD
Lenalidomide—Sinusitis—Doxorubicin—lung cancer	2.92e-05	0.000131	CcSEcCtD
Lenalidomide—Immune system disorder—Methotrexate—lung cancer	2.92e-05	0.000131	CcSEcCtD
Lenalidomide—Mediastinal disorder—Methotrexate—lung cancer	2.91e-05	0.00013	CcSEcCtD
Lenalidomide—Agranulocytosis—Doxorubicin—lung cancer	2.91e-05	0.00013	CcSEcCtD
Lenalidomide—Rash—Irinotecan—lung cancer	2.9e-05	0.00013	CcSEcCtD
Lenalidomide—Dermatitis—Irinotecan—lung cancer	2.9e-05	0.00013	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Docetaxel—lung cancer	2.9e-05	0.00013	CcSEcCtD
Lenalidomide—Chills—Methotrexate—lung cancer	2.9e-05	0.00013	CcSEcCtD
Lenalidomide—Headache—Irinotecan—lung cancer	2.89e-05	0.000129	CcSEcCtD
Lenalidomide—Insomnia—Docetaxel—lung cancer	2.88e-05	0.000129	CcSEcCtD
Lenalidomide—Diarrhoea—Cisplatin—lung cancer	2.86e-05	0.000128	CcSEcCtD
Lenalidomide—Paraesthesia—Docetaxel—lung cancer	2.86e-05	0.000128	CcSEcCtD
Lenalidomide—Alopecia—Methotrexate—lung cancer	2.85e-05	0.000128	CcSEcCtD
Lenalidomide—Vomiting—Gemcitabine—lung cancer	2.85e-05	0.000128	CcSEcCtD
Lenalidomide—Bradycardia—Doxorubicin—lung cancer	2.85e-05	0.000127	CcSEcCtD
Lenalidomide—Dyspnoea—Docetaxel—lung cancer	2.84e-05	0.000127	CcSEcCtD
Lenalidomide—Somnolence—Docetaxel—lung cancer	2.83e-05	0.000127	CcSEcCtD
Lenalidomide—Mental disorder—Methotrexate—lung cancer	2.83e-05	0.000127	CcSEcCtD
Lenalidomide—Rash—Gemcitabine—lung cancer	2.83e-05	0.000127	CcSEcCtD
Lenalidomide—Dermatitis—Gemcitabine—lung cancer	2.83e-05	0.000127	CcSEcCtD
Lenalidomide—Hypersensitivity—Etoposide—lung cancer	2.82e-05	0.000126	CcSEcCtD
Lenalidomide—Erythema—Methotrexate—lung cancer	2.81e-05	0.000126	CcSEcCtD
Lenalidomide—Malnutrition—Methotrexate—lung cancer	2.81e-05	0.000126	CcSEcCtD
Lenalidomide—Haemoglobin—Doxorubicin—lung cancer	2.81e-05	0.000126	CcSEcCtD
Lenalidomide—Headache—Gemcitabine—lung cancer	2.81e-05	0.000126	CcSEcCtD
Lenalidomide—Rhinitis—Doxorubicin—lung cancer	2.8e-05	0.000126	CcSEcCtD
Lenalidomide—Dyspepsia—Docetaxel—lung cancer	2.8e-05	0.000125	CcSEcCtD
Lenalidomide—Hepatitis—Doxorubicin—lung cancer	2.8e-05	0.000125	CcSEcCtD
Lenalidomide—Haemorrhage—Doxorubicin—lung cancer	2.8e-05	0.000125	CcSEcCtD
Lenalidomide—Hypoaesthesia—Doxorubicin—lung cancer	2.78e-05	0.000125	CcSEcCtD
Lenalidomide—Pharyngitis—Doxorubicin—lung cancer	2.78e-05	0.000124	CcSEcCtD
Lenalidomide—Decreased appetite—Docetaxel—lung cancer	2.77e-05	0.000124	CcSEcCtD
Lenalidomide—Hypersensitivity—Paclitaxel—lung cancer	2.77e-05	0.000124	CcSEcCtD
Lenalidomide—Urinary tract disorder—Doxorubicin—lung cancer	2.76e-05	0.000124	CcSEcCtD
Lenalidomide—Oedema peripheral—Doxorubicin—lung cancer	2.76e-05	0.000123	CcSEcCtD
Lenalidomide—Dysgeusia—Methotrexate—lung cancer	2.75e-05	0.000123	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Docetaxel—lung cancer	2.75e-05	0.000123	CcSEcCtD
Lenalidomide—Asthenia—Etoposide—lung cancer	2.75e-05	0.000123	CcSEcCtD
Lenalidomide—Connective tissue disorder—Doxorubicin—lung cancer	2.75e-05	0.000123	CcSEcCtD
Lenalidomide—Fatigue—Docetaxel—lung cancer	2.75e-05	0.000123	CcSEcCtD
Lenalidomide—Urethral disorder—Doxorubicin—lung cancer	2.74e-05	0.000123	CcSEcCtD
Lenalidomide—ABCB1—Allograft Rejection—VEGFA—lung cancer	2.74e-05	0.000285	CbGpPWpGaD
Lenalidomide—Nausea—Irinotecan—lung cancer	2.74e-05	0.000122	CcSEcCtD
Lenalidomide—Constipation—Docetaxel—lung cancer	2.72e-05	0.000122	CcSEcCtD
Lenalidomide—Pain—Docetaxel—lung cancer	2.72e-05	0.000122	CcSEcCtD
Lenalidomide—Back pain—Methotrexate—lung cancer	2.72e-05	0.000122	CcSEcCtD
Lenalidomide—Pruritus—Etoposide—lung cancer	2.71e-05	0.000121	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—CXCL8—lung cancer	2.71e-05	0.000282	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—HSD17B10—lung cancer	2.7e-05	0.000281	CbGpPWpGaD
Lenalidomide—Visual impairment—Doxorubicin—lung cancer	2.7e-05	0.000121	CcSEcCtD
Lenalidomide—Asthenia—Paclitaxel—lung cancer	2.7e-05	0.000121	CcSEcCtD
Lenalidomide—PTGS2—Disease—PGAM1—lung cancer	2.67e-05	0.000278	CbGpPWpGaD
Lenalidomide—Nausea—Gemcitabine—lung cancer	2.67e-05	0.000119	CcSEcCtD
Lenalidomide—Vomiting—Cisplatin—lung cancer	2.66e-05	0.000119	CcSEcCtD
Lenalidomide—PTGS2—C-MYB transcription factor network—HRAS—lung cancer	2.66e-05	0.000277	CbGpPWpGaD
Lenalidomide—Pruritus—Paclitaxel—lung cancer	2.66e-05	0.000119	CcSEcCtD
Lenalidomide—PTGS2—Spinal Cord Injury—MAPK3—lung cancer	2.65e-05	0.000276	CbGpPWpGaD
Lenalidomide—Vision blurred—Methotrexate—lung cancer	2.65e-05	0.000119	CcSEcCtD
Lenalidomide—Erythema multiforme—Doxorubicin—lung cancer	2.64e-05	0.000118	CcSEcCtD
Lenalidomide—Rash—Cisplatin—lung cancer	2.64e-05	0.000118	CcSEcCtD
Lenalidomide—Dermatitis—Cisplatin—lung cancer	2.63e-05	0.000118	CcSEcCtD
Lenalidomide—Feeling abnormal—Docetaxel—lung cancer	2.62e-05	0.000117	CcSEcCtD
Lenalidomide—Diarrhoea—Etoposide—lung cancer	2.62e-05	0.000117	CcSEcCtD
Lenalidomide—Eye disorder—Doxorubicin—lung cancer	2.61e-05	0.000117	CcSEcCtD
Lenalidomide—Ill-defined disorder—Methotrexate—lung cancer	2.61e-05	0.000117	CcSEcCtD
Lenalidomide—Tinnitus—Doxorubicin—lung cancer	2.61e-05	0.000117	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—FGFR1—lung cancer	2.61e-05	0.000271	CbGpPWpGaD
Lenalidomide—Gastrointestinal pain—Docetaxel—lung cancer	2.6e-05	0.000117	CcSEcCtD
Lenalidomide—Anaemia—Methotrexate—lung cancer	2.6e-05	0.000116	CcSEcCtD
Lenalidomide—Cardiac disorder—Doxorubicin—lung cancer	2.6e-05	0.000116	CcSEcCtD
Lenalidomide—Flushing—Doxorubicin—lung cancer	2.6e-05	0.000116	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—CASP3—lung cancer	2.59e-05	0.00027	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—IL2—lung cancer	2.59e-05	0.000269	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—MYC—lung cancer	2.58e-05	0.000269	CbGpPWpGaD
Lenalidomide—Diarrhoea—Paclitaxel—lung cancer	2.57e-05	0.000115	CcSEcCtD
Lenalidomide—Angiopathy—Doxorubicin—lung cancer	2.54e-05	0.000114	CcSEcCtD
Lenalidomide—Malaise—Methotrexate—lung cancer	2.54e-05	0.000113	CcSEcCtD
Lenalidomide—Dizziness—Etoposide—lung cancer	2.53e-05	0.000113	CcSEcCtD
Lenalidomide—Immune system disorder—Doxorubicin—lung cancer	2.53e-05	0.000113	CcSEcCtD
Lenalidomide—Vertigo—Methotrexate—lung cancer	2.53e-05	0.000113	CcSEcCtD
Lenalidomide—PTGS2—Spinal Cord Injury—EGFR—lung cancer	2.52e-05	0.000263	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CCND1—lung cancer	2.52e-05	0.000263	CbGpPWpGaD
Lenalidomide—Mediastinal disorder—Doxorubicin—lung cancer	2.52e-05	0.000113	CcSEcCtD
Lenalidomide—Abdominal pain—Docetaxel—lung cancer	2.52e-05	0.000113	CcSEcCtD
Lenalidomide—Body temperature increased—Docetaxel—lung cancer	2.52e-05	0.000113	CcSEcCtD
Lenalidomide—Leukopenia—Methotrexate—lung cancer	2.52e-05	0.000113	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—JUN—lung cancer	2.52e-05	0.000262	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—MDM2—lung cancer	2.51e-05	0.000262	CbGpPWpGaD
Lenalidomide—Chills—Doxorubicin—lung cancer	2.51e-05	0.000112	CcSEcCtD
Lenalidomide—PTGS2—Metabolism—CKB—lung cancer	2.51e-05	0.000261	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—RAF1—lung cancer	2.5e-05	0.000261	CbGpPWpGaD
Lenalidomide—Arrhythmia—Doxorubicin—lung cancer	2.5e-05	0.000112	CcSEcCtD
Lenalidomide—PTGS2—Disease—SDC4—lung cancer	2.49e-05	0.00026	CbGpPWpGaD
Lenalidomide—Dizziness—Paclitaxel—lung cancer	2.48e-05	0.000111	CcSEcCtD
Lenalidomide—Nausea—Cisplatin—lung cancer	2.48e-05	0.000111	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—ERBB2—lung cancer	2.48e-05	0.000258	CbGpPWpGaD
Lenalidomide—Alopecia—Doxorubicin—lung cancer	2.47e-05	0.000111	CcSEcCtD
Lenalidomide—Cough—Methotrexate—lung cancer	2.45e-05	0.00011	CcSEcCtD
Lenalidomide—PTGS2—Selenium Micronutrient Network—IL6—lung cancer	2.45e-05	0.000255	CbGpPWpGaD
Lenalidomide—Mental disorder—Doxorubicin—lung cancer	2.45e-05	0.00011	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—MMP9—lung cancer	2.45e-05	0.000255	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—ABCC3—lung cancer	2.45e-05	0.000255	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CDKN1A—lung cancer	2.44e-05	0.000254	CbGpPWpGaD
Lenalidomide—Vomiting—Etoposide—lung cancer	2.44e-05	0.000109	CcSEcCtD
Lenalidomide—Malnutrition—Doxorubicin—lung cancer	2.43e-05	0.000109	CcSEcCtD
Lenalidomide—Erythema—Doxorubicin—lung cancer	2.43e-05	0.000109	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—PTEN—lung cancer	2.43e-05	0.000253	CbGpPWpGaD
Lenalidomide—Rash—Etoposide—lung cancer	2.42e-05	0.000108	CcSEcCtD
Lenalidomide—Dermatitis—Etoposide—lung cancer	2.41e-05	0.000108	CcSEcCtD
Lenalidomide—Headache—Etoposide—lung cancer	2.4e-05	0.000107	CcSEcCtD
Lenalidomide—Flatulence—Doxorubicin—lung cancer	2.4e-05	0.000107	CcSEcCtD
Lenalidomide—Arthralgia—Methotrexate—lung cancer	2.39e-05	0.000107	CcSEcCtD
Lenalidomide—Myalgia—Methotrexate—lung cancer	2.39e-05	0.000107	CcSEcCtD
Lenalidomide—Chest pain—Methotrexate—lung cancer	2.39e-05	0.000107	CcSEcCtD
Lenalidomide—Tension—Doxorubicin—lung cancer	2.39e-05	0.000107	CcSEcCtD
Lenalidomide—Vomiting—Paclitaxel—lung cancer	2.39e-05	0.000107	CcSEcCtD
Lenalidomide—Dysgeusia—Doxorubicin—lung cancer	2.38e-05	0.000107	CcSEcCtD
Lenalidomide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lung cancer	2.38e-05	0.000106	CcSEcCtD
Lenalidomide—Rash—Paclitaxel—lung cancer	2.37e-05	0.000106	CcSEcCtD
Lenalidomide—Dermatitis—Paclitaxel—lung cancer	2.37e-05	0.000106	CcSEcCtD
Lenalidomide—Discomfort—Methotrexate—lung cancer	2.37e-05	0.000106	CcSEcCtD
Lenalidomide—Nervousness—Doxorubicin—lung cancer	2.36e-05	0.000106	CcSEcCtD
Lenalidomide—PTGS2—Metabolism—GSTM2—lung cancer	2.36e-05	0.000246	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—CNDP2—lung cancer	2.36e-05	0.000246	CbGpPWpGaD
Lenalidomide—Back pain—Doxorubicin—lung cancer	2.36e-05	0.000105	CcSEcCtD
Lenalidomide—Headache—Paclitaxel—lung cancer	2.35e-05	0.000105	CcSEcCtD
Lenalidomide—ABCB1—Metabolism—ATP5H—lung cancer	2.35e-05	0.000244	CbGpPWpGaD
Lenalidomide—Hypersensitivity—Docetaxel—lung cancer	2.35e-05	0.000105	CcSEcCtD
Lenalidomide—Muscle spasms—Doxorubicin—lung cancer	2.34e-05	0.000105	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—EP300—lung cancer	2.32e-05	0.000242	CbGpPWpGaD
Lenalidomide—Confusional state—Methotrexate—lung cancer	2.31e-05	0.000104	CcSEcCtD
Lenalidomide—PTGS2—Metabolism—MTMR3—lung cancer	2.3e-05	0.000239	CbGpPWpGaD
Lenalidomide—Vision blurred—Doxorubicin—lung cancer	2.29e-05	0.000103	CcSEcCtD
Lenalidomide—Asthenia—Docetaxel—lung cancer	2.28e-05	0.000102	CcSEcCtD
Lenalidomide—Infection—Methotrexate—lung cancer	2.28e-05	0.000102	CcSEcCtD
Lenalidomide—Nausea—Etoposide—lung cancer	2.28e-05	0.000102	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—APC—lung cancer	2.26e-05	0.000235	CbGpPWpGaD
Lenalidomide—Ill-defined disorder—Doxorubicin—lung cancer	2.26e-05	0.000101	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—SRC—lung cancer	2.26e-05	0.000235	CbGpPWpGaD
Lenalidomide—Pruritus—Docetaxel—lung cancer	2.25e-05	0.000101	CcSEcCtD
Lenalidomide—Nervous system disorder—Methotrexate—lung cancer	2.25e-05	0.000101	CcSEcCtD
Lenalidomide—Anaemia—Doxorubicin—lung cancer	2.25e-05	0.000101	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CASP3—lung cancer	2.25e-05	0.000234	CbGpPWpGaD
Lenalidomide—Thrombocytopenia—Methotrexate—lung cancer	2.25e-05	0.000101	CcSEcCtD
Lenalidomide—Agitation—Doxorubicin—lung cancer	2.24e-05	0.0001	CcSEcCtD
Lenalidomide—PTGS2—Metabolism—PGAM1—lung cancer	2.24e-05	0.000233	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—EGF—lung cancer	2.23e-05	0.000233	CbGpPWpGaD
Lenalidomide—Nausea—Paclitaxel—lung cancer	2.23e-05	9.99e-05	CcSEcCtD
Lenalidomide—Skin disorder—Methotrexate—lung cancer	2.23e-05	9.98e-05	CcSEcCtD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—GNG11—lung cancer	2.22e-05	0.000231	CbGpPWpGaD
Lenalidomide—Hyperhidrosis—Methotrexate—lung cancer	2.22e-05	9.93e-05	CcSEcCtD
Lenalidomide—PTGS2—Disease—SKI—lung cancer	2.2e-05	0.000229	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—VEGFA—lung cancer	2.2e-05	0.000229	CbGpPWpGaD
Lenalidomide—Malaise—Doxorubicin—lung cancer	2.2e-05	9.83e-05	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—lung cancer	2.19e-05	0.000228	CbGpPWpGaD
Lenalidomide—Vertigo—Doxorubicin—lung cancer	2.19e-05	9.79e-05	CcSEcCtD
Lenalidomide—Anorexia—Methotrexate—lung cancer	2.19e-05	9.79e-05	CcSEcCtD
Lenalidomide—Syncope—Doxorubicin—lung cancer	2.18e-05	9.77e-05	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—JUN—lung cancer	2.18e-05	0.000227	CbGpPWpGaD
Lenalidomide—Leukopenia—Doxorubicin—lung cancer	2.18e-05	9.76e-05	CcSEcCtD
Lenalidomide—Diarrhoea—Docetaxel—lung cancer	2.18e-05	9.75e-05	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—STAT3—lung cancer	2.18e-05	0.000227	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—NRAS—lung cancer	2.17e-05	0.000226	CbGpPWpGaD
Lenalidomide—Palpitations—Doxorubicin—lung cancer	2.15e-05	9.63e-05	CcSEcCtD
Lenalidomide—Hypotension—Methotrexate—lung cancer	2.14e-05	9.6e-05	CcSEcCtD
Lenalidomide—Loss of consciousness—Doxorubicin—lung cancer	2.14e-05	9.58e-05	CcSEcCtD
Lenalidomide—PTGS2—Disease—B4GALT5—lung cancer	2.14e-05	0.000222	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—CYP2A7—lung cancer	2.13e-05	0.000222	CbGpPWpGaD
Lenalidomide—Cough—Doxorubicin—lung cancer	2.12e-05	9.51e-05	CcSEcCtD
Lenalidomide—PTGS2—Spinal Cord Injury—TP53—lung cancer	2.12e-05	0.000221	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1A—lung cancer	2.12e-05	0.00022	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—PTEN—lung cancer	2.11e-05	0.00022	CbGpPWpGaD
Lenalidomide—Dizziness—Docetaxel—lung cancer	2.11e-05	9.42e-05	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CASP8—lung cancer	2.11e-05	0.000219	CbGpPWpGaD
Lenalidomide—Hypertension—Doxorubicin—lung cancer	2.1e-05	9.41e-05	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CREBBP—lung cancer	2.1e-05	0.000218	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PLBD1—lung cancer	2.09e-05	0.000218	CbGpPWpGaD
Lenalidomide—Musculoskeletal discomfort—Methotrexate—lung cancer	2.09e-05	9.36e-05	CcSEcCtD
Lenalidomide—PTGS2—Metabolism—SDC4—lung cancer	2.09e-05	0.000217	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—MAPK3—lung cancer	2.08e-05	0.000217	CbGpPWpGaD
Lenalidomide—Insomnia—Methotrexate—lung cancer	2.08e-05	9.29e-05	CcSEcCtD
Lenalidomide—Chest pain—Doxorubicin—lung cancer	2.07e-05	9.28e-05	CcSEcCtD
Lenalidomide—Arthralgia—Doxorubicin—lung cancer	2.07e-05	9.28e-05	CcSEcCtD
Lenalidomide—Myalgia—Doxorubicin—lung cancer	2.07e-05	9.28e-05	CcSEcCtD
Lenalidomide—Anxiety—Doxorubicin—lung cancer	2.07e-05	9.25e-05	CcSEcCtD
Lenalidomide—Paraesthesia—Methotrexate—lung cancer	2.06e-05	9.22e-05	CcSEcCtD
Lenalidomide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—lung cancer	2.06e-05	9.21e-05	CcSEcCtD
Lenalidomide—Discomfort—Doxorubicin—lung cancer	2.05e-05	9.17e-05	CcSEcCtD
Lenalidomide—Dyspnoea—Methotrexate—lung cancer	2.05e-05	9.16e-05	CcSEcCtD
Lenalidomide—Somnolence—Methotrexate—lung cancer	2.04e-05	9.13e-05	CcSEcCtD
Lenalidomide—Dry mouth—Doxorubicin—lung cancer	2.03e-05	9.07e-05	CcSEcCtD
Lenalidomide—Vomiting—Docetaxel—lung cancer	2.02e-05	9.06e-05	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—MYC—lung cancer	2.02e-05	0.000211	CbGpPWpGaD
Lenalidomide—Dyspepsia—Methotrexate—lung cancer	2.02e-05	9.04e-05	CcSEcCtD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—AKT1—lung cancer	2.02e-05	0.00021	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—EP300—lung cancer	2.01e-05	0.00021	CbGpPWpGaD
Lenalidomide—Rash—Docetaxel—lung cancer	2.01e-05	8.99e-05	CcSEcCtD
Lenalidomide—Dermatitis—Docetaxel—lung cancer	2.01e-05	8.98e-05	CcSEcCtD
Lenalidomide—Confusional state—Doxorubicin—lung cancer	2e-05	8.97e-05	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—MAP2K1—lung cancer	2e-05	0.000208	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—ADCY1—lung cancer	2e-05	0.000208	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—ABCG2—lung cancer	2e-05	0.000208	CbGpPWpGaD
Lenalidomide—Decreased appetite—Methotrexate—lung cancer	1.99e-05	8.93e-05	CcSEcCtD
Lenalidomide—Headache—Docetaxel—lung cancer	1.99e-05	8.93e-05	CcSEcCtD
Lenalidomide—Oedema—Doxorubicin—lung cancer	1.99e-05	8.89e-05	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Methotrexate—lung cancer	1.98e-05	8.87e-05	CcSEcCtD
Lenalidomide—Fatigue—Methotrexate—lung cancer	1.98e-05	8.86e-05	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—EGFR—lung cancer	1.98e-05	0.000206	CbGpPWpGaD
Lenalidomide—Infection—Doxorubicin—lung cancer	1.97e-05	8.84e-05	CcSEcCtD
Lenalidomide—Pain—Methotrexate—lung cancer	1.96e-05	8.78e-05	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—SRC—lung cancer	1.96e-05	0.000204	CbGpPWpGaD
Lenalidomide—Shock—Doxorubicin—lung cancer	1.96e-05	8.75e-05	CcSEcCtD
Lenalidomide—Nervous system disorder—Doxorubicin—lung cancer	1.95e-05	8.72e-05	CcSEcCtD
Lenalidomide—Thrombocytopenia—Doxorubicin—lung cancer	1.95e-05	8.71e-05	CcSEcCtD
Lenalidomide—Tachycardia—Doxorubicin—lung cancer	1.94e-05	8.68e-05	CcSEcCtD
Lenalidomide—PTGS2—Spinal Cord Injury—IL6—lung cancer	1.94e-05	0.000202	CbGpPWpGaD
Lenalidomide—Skin disorder—Doxorubicin—lung cancer	1.93e-05	8.64e-05	CcSEcCtD
Lenalidomide—Hyperhidrosis—Doxorubicin—lung cancer	1.92e-05	8.6e-05	CcSEcCtD
Lenalidomide—ABCB1—Metabolism—HSD17B10—lung cancer	1.91e-05	0.000199	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—PXN—lung cancer	1.91e-05	0.000199	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—lung cancer	1.91e-05	0.000199	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—RRM1—lung cancer	1.9e-05	0.000198	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—GSTA3—lung cancer	1.9e-05	0.000198	CbGpPWpGaD
Lenalidomide—Anorexia—Doxorubicin—lung cancer	1.89e-05	8.48e-05	CcSEcCtD
Lenalidomide—Nausea—Docetaxel—lung cancer	1.89e-05	8.47e-05	CcSEcCtD
Lenalidomide—Feeling abnormal—Methotrexate—lung cancer	1.89e-05	8.46e-05	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Methotrexate—lung cancer	1.88e-05	8.4e-05	CcSEcCtD
Lenalidomide—PTGS2—Disease—AKR1C1—lung cancer	1.87e-05	0.000195	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—KRAS—lung cancer	1.87e-05	0.000195	CbGpPWpGaD
Lenalidomide—Hypotension—Doxorubicin—lung cancer	1.86e-05	8.31e-05	CcSEcCtD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—TF—lung cancer	1.85e-05	0.000193	CbGpPWpGaD
Lenalidomide—Urticaria—Methotrexate—lung cancer	1.82e-05	8.16e-05	CcSEcCtD
Lenalidomide—Abdominal pain—Methotrexate—lung cancer	1.81e-05	8.12e-05	CcSEcCtD
Lenalidomide—Body temperature increased—Methotrexate—lung cancer	1.81e-05	8.12e-05	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Doxorubicin—lung cancer	1.81e-05	8.1e-05	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—MAPK3—lung cancer	1.8e-05	0.000188	CbGpPWpGaD
Lenalidomide—Insomnia—Doxorubicin—lung cancer	1.8e-05	8.04e-05	CcSEcCtD
Lenalidomide—PTGS2—Metabolism—B4GALT5—lung cancer	1.79e-05	0.000186	CbGpPWpGaD
Lenalidomide—Paraesthesia—Doxorubicin—lung cancer	1.78e-05	7.99e-05	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—lung cancer	1.78e-05	0.000185	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—CKB—lung cancer	1.78e-05	0.000185	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—RAF1—lung cancer	1.77e-05	0.000185	CbGpPWpGaD
Lenalidomide—Dyspnoea—Doxorubicin—lung cancer	1.77e-05	7.93e-05	CcSEcCtD
Lenalidomide—Somnolence—Doxorubicin—lung cancer	1.77e-05	7.91e-05	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—lung cancer	1.76e-05	0.000183	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—lung cancer	1.75e-05	0.000183	CbGpPWpGaD
Lenalidomide—Dyspepsia—Doxorubicin—lung cancer	1.75e-05	7.83e-05	CcSEcCtD
Lenalidomide—PTGS2—Metabolism—GSTA4—lung cancer	1.74e-05	0.000181	CbGpPWpGaD
Lenalidomide—Decreased appetite—Doxorubicin—lung cancer	1.73e-05	7.73e-05	CcSEcCtD
Lenalidomide—PTGS2—Disease—NPPA—lung cancer	1.72e-05	0.000179	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—PIK3CA—lung cancer	1.72e-05	0.000179	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—lung cancer	1.72e-05	0.000179	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—lung cancer	1.72e-05	0.000179	CbGpPWpGaD
Lenalidomide—Gastrointestinal disorder—Doxorubicin—lung cancer	1.72e-05	7.68e-05	CcSEcCtD
Lenalidomide—Fatigue—Doxorubicin—lung cancer	1.71e-05	7.67e-05	CcSEcCtD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—CYP1A1—lung cancer	1.7e-05	0.000177	CbGpPWpGaD
Lenalidomide—Pain—Doxorubicin—lung cancer	1.7e-05	7.61e-05	CcSEcCtD
Lenalidomide—Constipation—Doxorubicin—lung cancer	1.7e-05	7.61e-05	CcSEcCtD
Lenalidomide—PTGS2—Metabolism—GSTA2—lung cancer	1.7e-05	0.000177	CbGpPWpGaD
Lenalidomide—Hypersensitivity—Methotrexate—lung cancer	1.69e-05	7.57e-05	CcSEcCtD
Lenalidomide—PTGS2—Disease—PPIA—lung cancer	1.68e-05	0.000175	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—GSTM2—lung cancer	1.67e-05	0.000174	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—CNDP2—lung cancer	1.67e-05	0.000174	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—ALDOA—lung cancer	1.67e-05	0.000174	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—TP53—lung cancer	1.66e-05	0.000173	CbGpPWpGaD
Lenalidomide—Asthenia—Methotrexate—lung cancer	1.65e-05	7.37e-05	CcSEcCtD
Lenalidomide—Feeling abnormal—Doxorubicin—lung cancer	1.64e-05	7.33e-05	CcSEcCtD
Lenalidomide—PTGS2—Metabolism—GSTA1—lung cancer	1.64e-05	0.00017	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—MTMR3—lung cancer	1.63e-05	0.000169	CbGpPWpGaD
Lenalidomide—Gastrointestinal pain—Doxorubicin—lung cancer	1.62e-05	7.27e-05	CcSEcCtD
Lenalidomide—Pruritus—Methotrexate—lung cancer	1.62e-05	7.27e-05	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—lung cancer	1.62e-05	0.000169	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—ABCC3—lung cancer	1.62e-05	0.000168	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—lung cancer	1.59e-05	0.000166	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—HRAS—lung cancer	1.59e-05	0.000165	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PGAM1—lung cancer	1.59e-05	0.000165	CbGpPWpGaD
Lenalidomide—Urticaria—Doxorubicin—lung cancer	1.58e-05	7.07e-05	CcSEcCtD
Lenalidomide—PTGS2—Disease—ADCY1—lung cancer	1.57e-05	0.000164	CbGpPWpGaD
Lenalidomide—Abdominal pain—Doxorubicin—lung cancer	1.57e-05	7.03e-05	CcSEcCtD
Lenalidomide—Body temperature increased—Doxorubicin—lung cancer	1.57e-05	7.03e-05	CcSEcCtD
Lenalidomide—Diarrhoea—Methotrexate—lung cancer	1.57e-05	7.03e-05	CcSEcCtD
Lenalidomide—PTGS2—Metabolism—AKR1C1—lung cancer	1.57e-05	0.000163	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—lung cancer	1.55e-05	0.000161	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—lung cancer	1.55e-05	0.000161	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—ENO2—lung cancer	1.54e-05	0.000161	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—PPP2R1B—lung cancer	1.53e-05	0.00016	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—SMARCA4—lung cancer	1.53e-05	0.00016	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—IL6—lung cancer	1.52e-05	0.000158	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—UGT1A1—lung cancer	1.52e-05	0.000158	CbGpPWpGaD
Lenalidomide—Dizziness—Methotrexate—lung cancer	1.52e-05	6.79e-05	CcSEcCtD
Lenalidomide—ABCB1—Metabolism—CYP2A7—lung cancer	1.51e-05	0.000158	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—lung cancer	1.5e-05	0.000156	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—lung cancer	1.5e-05	0.000156	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—lung cancer	1.49e-05	0.000155	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—SDC4—lung cancer	1.48e-05	0.000154	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—GNG11—lung cancer	1.47e-05	0.000153	CbGpPWpGaD
Lenalidomide—Hypersensitivity—Doxorubicin—lung cancer	1.46e-05	6.55e-05	CcSEcCtD
Lenalidomide—Vomiting—Methotrexate—lung cancer	1.46e-05	6.53e-05	CcSEcCtD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—APOA1—lung cancer	1.46e-05	0.000152	CbGpPWpGaD
Lenalidomide—Rash—Methotrexate—lung cancer	1.45e-05	6.48e-05	CcSEcCtD
Lenalidomide—Dermatitis—Methotrexate—lung cancer	1.45e-05	6.47e-05	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—lung cancer	1.44e-05	0.00015	CbGpPWpGaD
Lenalidomide—Headache—Methotrexate—lung cancer	1.44e-05	6.43e-05	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—lung cancer	1.43e-05	0.000149	CbGpPWpGaD
Lenalidomide—Asthenia—Doxorubicin—lung cancer	1.43e-05	6.38e-05	CcSEcCtD
Lenalidomide—Pruritus—Doxorubicin—lung cancer	1.41e-05	6.29e-05	CcSEcCtD
Lenalidomide—PTGS2—Disease—ENO1—lung cancer	1.4e-05	0.000146	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—AKT1—lung cancer	1.4e-05	0.000146	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—ALDOA—lung cancer	1.4e-05	0.000145	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—lung cancer	1.39e-05	0.000145	CbGpPWpGaD
Lenalidomide—Nausea—Methotrexate—lung cancer	1.36e-05	6.1e-05	CcSEcCtD
Lenalidomide—Diarrhoea—Doxorubicin—lung cancer	1.36e-05	6.09e-05	CcSEcCtD
Lenalidomide—PTGS2—Metabolism—NCOA3—lung cancer	1.36e-05	0.000141	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—lung cancer	1.35e-05	0.000141	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—RRM1—lung cancer	1.35e-05	0.00014	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—GSTA3—lung cancer	1.35e-05	0.00014	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—PIK3CG—lung cancer	1.33e-05	0.000139	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—ADCY1—lung cancer	1.32e-05	0.000137	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—ABCG2—lung cancer	1.32e-05	0.000137	CbGpPWpGaD
Lenalidomide—Dizziness—Doxorubicin—lung cancer	1.31e-05	5.88e-05	CcSEcCtD
Lenalidomide—PTGS2—Disease—APP—lung cancer	1.3e-05	0.000136	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—FGF9—lung cancer	1.29e-05	0.000135	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—ENO2—lung cancer	1.29e-05	0.000135	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—HPGDS—lung cancer	1.29e-05	0.000135	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—AVP—lung cancer	1.29e-05	0.000134	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PPP2R1B—lung cancer	1.28e-05	0.000134	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—lung cancer	1.28e-05	0.000133	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—POMC—lung cancer	1.27e-05	0.000132	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—B4GALT5—lung cancer	1.27e-05	0.000132	CbGpPWpGaD
Lenalidomide—Vomiting—Doxorubicin—lung cancer	1.26e-05	5.66e-05	CcSEcCtD
Lenalidomide—PTGS2—Metabolism—GSTT1—lung cancer	1.25e-05	0.000131	CbGpPWpGaD
Lenalidomide—Rash—Doxorubicin—lung cancer	1.25e-05	5.61e-05	CcSEcCtD
Lenalidomide—Dermatitis—Doxorubicin—lung cancer	1.25e-05	5.6e-05	CcSEcCtD
Lenalidomide—Headache—Doxorubicin—lung cancer	1.24e-05	5.57e-05	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—lung cancer	1.24e-05	0.00013	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—GCLC—lung cancer	1.24e-05	0.000129	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—CYP2A6—lung cancer	1.24e-05	0.000129	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—JUNB—lung cancer	1.24e-05	0.000129	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—CREBBP—lung cancer	1.23e-05	0.000129	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—GSTA4—lung cancer	1.23e-05	0.000128	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—lung cancer	1.22e-05	0.000127	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—lung cancer	1.22e-05	0.000127	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—GSTA2—lung cancer	1.2e-05	0.000125	CbGpPWpGaD
Lenalidomide—Nausea—Doxorubicin—lung cancer	1.18e-05	5.28e-05	CcSEcCtD
Lenalidomide—PTGS2—Metabolism—ENO1—lung cancer	1.17e-05	0.000122	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—PIK3CD—lung cancer	1.17e-05	0.000122	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—GSTA1—lung cancer	1.16e-05	0.000121	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—ALB—lung cancer	1.16e-05	0.00012	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—lung cancer	1.15e-05	0.00012	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—ABCC3—lung cancer	1.15e-05	0.000119	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—AKR1C1—lung cancer	1.11e-05	0.000116	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—FOXO3—lung cancer	1.08e-05	0.000113	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—UGT1A1—lung cancer	1.08e-05	0.000112	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—lung cancer	1.06e-05	0.00011	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—CYP2E1—lung cancer	1.05e-05	0.00011	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—NQO1—lung cancer	1.04e-05	0.000109	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—GNG11—lung cancer	1.04e-05	0.000108	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—lung cancer	1.02e-05	0.000106	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—PIK3CB—lung cancer	1.02e-05	0.000106	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—ALDOA—lung cancer	9.9e-06	0.000103	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—APOA1—lung cancer	9.83e-06	0.000102	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—NCOA3—lung cancer	9.61e-06	0.0001	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—HES1—lung cancer	9.59e-06	9.99e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—STK11—lung cancer	9.39e-06	9.78e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—ADCY1—lung cancer	9.34e-06	9.73e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—ABCG2—lung cancer	9.34e-06	9.73e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—ENO2—lung cancer	9.16e-06	9.54e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—HPGDS—lung cancer	9.16e-06	9.54e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PPP2R1B—lung cancer	9.11e-06	9.48e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—ERCC2—lung cancer	8.97e-06	9.34e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—GSTT1—lung cancer	8.89e-06	9.26e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—PTEN—lung cancer	8.82e-06	9.18e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—CYP2A6—lung cancer	8.79e-06	9.15e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—GCLC—lung cancer	8.79e-06	9.15e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—ERBB3—lung cancer	8.77e-06	9.13e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—GSTP1—lung cancer	8.69e-06	9.05e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—lung cancer	8.63e-06	8.98e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—CAT—lung cancer	8.46e-06	8.81e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—EP300—lung cancer	8.41e-06	8.76e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—TERT—lung cancer	8.4e-06	8.75e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—ENO1—lung cancer	8.33e-06	8.67e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—CREBBP—lung cancer	8.32e-06	8.67e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—ABCB1—lung cancer	8.23e-06	8.57e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—FGFR1—lung cancer	8.16e-06	8.5e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—TYMS—lung cancer	8.08e-06	8.41e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—HIF1A—lung cancer	8.04e-06	8.37e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—GSTM1—lung cancer	7.99e-06	8.32e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—ALB—lung cancer	7.79e-06	8.11e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—APOA1—lung cancer	7.76e-06	8.08e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—CYP1A1—lung cancer	7.57e-06	7.88e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—ERCC2—lung cancer	7.51e-06	7.82e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—CYP2E1—lung cancer	7.47e-06	7.78e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—NQO1—lung cancer	7.39e-06	7.69e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—KIT—lung cancer	7.08e-06	7.37e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—APC—lung cancer	7.08e-06	7.37e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—RAF1—lung cancer	7.04e-06	7.34e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—EGF—lung cancer	7e-06	7.29e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—STK11—lung cancer	6.66e-06	6.93e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—BRAF—lung cancer	6.66e-06	6.93e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—IL6R—lung cancer	6.58e-06	6.85e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—CREBBP—lung cancer	6.57e-06	6.84e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—APOA1—lung cancer	6.5e-06	6.76e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—MAP2K1—lung cancer	6.27e-06	6.53e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—PIK3CD—lung cancer	6.23e-06	6.48e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	6.22e-06	6.48e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—GSTP1—lung cancer	6.16e-06	6.42e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—CAT—lung cancer	6e-06	6.24e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PIK3CG—lung cancer	5.93e-06	6.18e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—TYMS—lung cancer	5.73e-06	5.96e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—GSTM1—lung cancer	5.66e-06	5.9e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—POMC—lung cancer	5.65e-06	5.88e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—MDM2—lung cancer	5.58e-06	5.81e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—RAF1—lung cancer	5.56e-06	5.79e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—CREBBP—lung cancer	5.5e-06	5.73e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—ERBB2—lung cancer	5.5e-06	5.73e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—MTOR—lung cancer	5.43e-06	5.65e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—PIK3CB—lung cancer	5.43e-06	5.65e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—CD4—lung cancer	5.42e-06	5.64e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—CYP1A1—lung cancer	5.37e-06	5.59e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—ERCC2—lung cancer	5.32e-06	5.54e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PIK3CD—lung cancer	5.21e-06	5.43e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—ALB—lung cancer	5.15e-06	5.36e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—CDKN1A—lung cancer	4.7e-06	4.89e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—PTEN—lung cancer	4.69e-06	4.88e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—APOA1—lung cancer	4.6e-06	4.8e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PIK3CB—lung cancer	4.54e-06	4.73e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—EP300—lung cancer	4.47e-06	4.66e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—SRC—lung cancer	4.35e-06	4.53e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PIK3CG—lung cancer	4.2e-06	4.38e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—STAT3—lung cancer	4.19e-06	4.37e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—NRAS—lung cancer	4.18e-06	4.36e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—MAPK3—lung cancer	4.01e-06	4.17e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—POMC—lung cancer	4e-06	4.17e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PTEN—lung cancer	3.93e-06	4.09e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—CREBBP—lung cancer	3.9e-06	4.06e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—MYC—lung cancer	3.9e-06	4.06e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—EGFR—lung cancer	3.81e-06	3.97e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—EP300—lung cancer	3.74e-06	3.9e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PIK3CD—lung cancer	3.7e-06	3.85e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—ALB—lung cancer	3.65e-06	3.8e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—KRAS—lung cancer	3.6e-06	3.75e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—PIK3CA—lung cancer	3.31e-06	3.44e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PIK3CB—lung cancer	3.22e-06	3.35e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PTGS2—lung cancer	3.19e-06	3.32e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—HRAS—lung cancer	3.06e-06	3.19e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—IL6—lung cancer	2.93e-06	3.05e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PTEN—lung cancer	2.78e-06	2.9e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PIK3CA—lung cancer	2.77e-06	2.88e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—AKT1—lung cancer	2.7e-06	2.81e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—EP300—lung cancer	2.65e-06	2.76e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—AKT1—lung cancer	2.26e-06	2.36e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PIK3CA—lung cancer	1.96e-06	2.04e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—AKT1—lung cancer	1.6e-06	1.67e-05	CbGpPWpGaD
